Key result
Moderate aortic stenosis carries substantial excess mortality, highlighting an urgent need for targeted intervention.
Why the study?
Moderate AS is associated with significant morbidity and mortality, yet current guidelines recommend valve replacement only for severe AS or moderate AS with a concomitant surgical indication, leaving a therapeutic gap.
Answers are grounded in this paper and cite their sources.
This review summarizes the pathophysiology, diagnostic challenges, prognostic markers, and evolving therapeutic strategies (including TAVR and pharmacotherapies) to address the management gap in patients with moderate aortic stenosis.
Aortic stenosis (AS) is a progressive valvular disease with rising incidence, particularly among elderly populations. Although excess mortality in severe AS is well recognised, moderate AS is also associated with significant morbidity and mortality. Current guidelines recommend valve replacement only for severe AS or in moderate AS with a concomitant surgical indication, leaving a therapeutic gap. This review summarises current knowledge on the epidemiology, pathophysiology, natural history and diagnostic challenges of AS management, with an emphasis on moderate disease. We discuss prognostic markers, including myocardial fibrosis, reduced left ventricular ejection fraction, global longitudinal strain and autonomic dysfunction, that may identify high-risk moderate AS patients. Evidence from recent and ongoing trials of transcatheter aortic valve replacement and novel pharmacotherapies is summarised, and limitations of existing valve prostheses and medical therapies are discussed. Improved risk stratification, earlier detection of pathological changes and targeted intervention may ultimately improve the management paradigm for moderate AS.
No takes yet. Share an insight, caveat, or question.
Connolly et al. (2026) conducted a review in Moderate aortic stenosis. Transcatheter aortic valve replacement and novel pharmacotherapies was evaluated. Moderate aortic stenosis carries significant morbidity and mortality, and improved risk stratification with targeted interventions may address the current therapeutic gap.
Synapse has enriched 10 related papers. Consider them for comparative context: